{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:45:53Z","timestamp":1791909953488,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63269-6","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T15:42:04Z","timestamp":1755963724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-8369","authenticated-orcid":false,"given":"Xiaotong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-7732","authenticated-orcid":false,"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"63269_CR1","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","volume":"13","author":"SJ Scales","year":"2014","unstructured":"Scales, S. J. et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol. Cancer Ther. 13, 2630\u20132640 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"63269_CR2","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","volume":"34","author":"R Hassan","year":"2016","unstructured":"Hassan, R. et al. Mesothelin immunotherapy for cancer: ready for prime time? J. Clin. Oncol. 34, 4171\u20134179 (2016).","journal-title":"J. Clin. Oncol."},{"key":"63269_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14740\/wjon1655","volume":"14","author":"BL Hagerty","year":"2023","unstructured":"Hagerty, B. L. & Takabe, K. Biology of mesothelin and clinical implications: a review of existing literature. World J. Oncol. 14, 340\u2013349 (2023).","journal-title":"World J. Oncol."},{"key":"63269_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/biology11111589","volume":"11","author":"T Nishio","year":"2022","unstructured":"Nishio, T. et al. The role of mesothelin in activation of portal fibroblasts in cholestatic liver injury. Biology 11, 1589 (2022).","journal-title":"Biology"},{"key":"63269_CR5","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"63269_CR6","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1074\/jbc.M806776200","volume":"284","author":"O Kaneko","year":"2009","unstructured":"Kaneko, O. et al. A binding domain on mesothelin for CA125\/MUC16. J. Biol. Chem. 284, 3739\u20133749 (2009).","journal-title":"J. Biol. Chem."},{"key":"63269_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1739408","volume":"12","author":"E Hatterer","year":"2020","unstructured":"Hatterer, E. et al. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. MAbs 12, 1739408 (2020).","journal-title":"MAbs"},{"key":"63269_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202439119","volume":"119","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proc. Natl. Acad. Sci. USA 119, e2202439119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63269_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-23-0233","volume":"23","author":"A Chakraborty","year":"2024","unstructured":"Chakraborty, A. et al. A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin. Mol. Cancer Ther. 23, 1021\u20131030 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"63269_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641\u2013661 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63269_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corvaia, N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63269_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40259-020-00429-8","volume":"34","author":"MT Stumpp","year":"2020","unstructured":"Stumpp, M. T., Dawson, K. M. & Binz, H. K. Beyond antibodies: the DARPin\u00ae drug platform. BioDrugs 34, 423\u2013433 (2020).","journal-title":"BioDrugs"},{"key":"63269_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pluckthun","year":"2015","unstructured":"Pluckthun, A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharm. Toxicol. 55, 489\u2013511 (2015).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"63269_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"63269_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"63269_CR16","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/jcmm.14356","volume":"23","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J. Cell Mol. Med. 23, 4854\u20134865 (2019).","journal-title":"J. Cell Mol. Med."},{"key":"63269_CR17","doi-asserted-by":"publisher","first-page":"e007572","DOI":"10.1136\/jitc-2023-007572","volume":"11","author":"E Gray","year":"2023","unstructured":"Gray, E. et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J. Immunother. Cancer 11, e007572 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"63269_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicolo","year":"2022","unstructured":"Nicolo, E. et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat. Rev. 106, 102395 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"63269_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes, C. J. et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J. Clin. Oncol. 41, 22\u201331 (2023).","journal-title":"J. Clin. Oncol."},{"key":"63269_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2020.08.004","volume":"327","author":"F Brandl","year":"2020","unstructured":"Brandl, F., Busslinger, S., Zangemeister-Wittke, U. & Pluckthun, A. Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. J. Control Release 327, 186\u2013197 (2020).","journal-title":"J. Control Release"},{"key":"63269_CR21","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1038\/s41586-024-08416-7","volume":"636","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Addendum: Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 636, E4 (2024).","journal-title":"Nature"},{"key":"63269_CR22","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/s41596-020-0312-x","volume":"15","author":"Y Yan","year":"2020","unstructured":"Yan, Y., Tao, H., He, J. & Huang, S. Y. The HDOCK server for integrated protein-protein docking. Nat. Protoc. 15, 1829\u20131852 (2020).","journal-title":"Nat. Protoc."},{"key":"63269_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","volume":"60","author":"M Gebauer","year":"2020","unstructured":"Gebauer, M. & Skerra, A. Engineered protein scaffolds as next-generation therapeutics. Annu. Rev. Pharm. Toxicol. 60, 391\u2013415 (2020).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"63269_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13238-017-0386-6","volume":"9","author":"R Simeon","year":"2018","unstructured":"Simeon, R. & Chen, Z. In vitro-engineered non-antibody protein therapeutics. Protein Cell 9, 3\u201314 (2018).","journal-title":"Protein Cell"},{"key":"63269_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2019.06.030","volume":"307","author":"F Brandl","year":"2019","unstructured":"Brandl, F. et al. Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. J. Control Release 307, 379\u2013392 (2019).","journal-title":"J. Control Release"},{"key":"63269_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jbiotec.2017.05.017","volume":"253","author":"C Cantante","year":"2017","unstructured":"Cantante, C. et al. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. J. Biotechnol. 253, 23\u201333 (2017).","journal-title":"J. Biotechnol."},{"key":"63269_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1021\/acs.biomac.7b01545","volume":"19","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Extending half life of H-Ferritin nanoparticle by fusing albumin binding domain for doxorubicin encapsulation. Biomacromolecules 19, 773\u2013781 (2018).","journal-title":"Biomacromolecules"},{"key":"63269_CR28","doi-asserted-by":"publisher","first-page":"e202113649","DOI":"10.1002\/anie.202113649","volume":"61","author":"MD Wang","year":"2022","unstructured":"Wang, M. D., Lv, G. T., An, H. W., Zhang, N. Y. & Wang, H. In situ self-assembly of bispecific peptide for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 61, e202113649 (2022).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"63269_CR29","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/bc4004102","volume":"24","author":"M Simon","year":"2013","unstructured":"Simon, M., Frey, R., Zangemeister-Wittke, U. & Pluckthun, A. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjug. Chem. 24, 1955\u20131966 (2013).","journal-title":"Bioconjug. Chem."},{"key":"63269_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/14728222.2013.740461","volume":"17","author":"CS Gondi","year":"2013","unstructured":"Gondi, C. S. & Rao, J. S. Cathepsin B as a cancer target. Expert Opin. Ther. Targets 17, 281\u2013291 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"63269_CR31","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody-drug conjugates. Chem. Soc. Rev. 48, 4361\u20134374 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"63269_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2008.02.012","volume":"62","author":"K Iwahori","year":"2008","unstructured":"Iwahori, K. et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 62, 45\u201354 (2008).","journal-title":"Lung Cancer"},{"key":"63269_CR33","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919\u20131929 (2019).","journal-title":"Mol. Ther."},{"key":"63269_CR34","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco, J. A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458\u20131465 (2003).","journal-title":"Blood"},{"key":"63269_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li, J. Y. et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 29, 117\u2013129 (2016).","journal-title":"Cancer Cell"},{"key":"63269_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib7020016","volume":"7","author":"MP Deonarain","year":"2018","unstructured":"Deonarain, M. P. et al. Small-format drug conjugates: a viable alternative to ADCs for solid tumours? Antibodies 7, 16 (2018).","journal-title":"Antibodies"},{"key":"63269_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ddtec.2018.10.005","volume":"30","author":"DA Richards","year":"2018","unstructured":"Richards, D. A. Exploring alternative antibody scaffolds: antibody fragments and antibody mimics for targeted drug delivery. Drug Discov. Today Technol. 30, 35\u201346 (2018).","journal-title":"Drug Discov. Today Technol."},{"key":"63269_CR38","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/pharmaceutics15082160","volume":"15","author":"A Kondrashov","year":"2023","unstructured":"Kondrashov, A. et al. Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload. Pharmaceutics 15, 2160 (2023).","journal-title":"Pharmaceutics"},{"key":"63269_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejpb.2021.07.011","volume":"167","author":"H Merten","year":"2021","unstructured":"Merten, H. et al. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. Eur. J. Pharm. Biopharm. 167, 104\u2013113 (2021).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"63269_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/biomedicines9040397","volume":"9","author":"S Weidemann","year":"2021","unstructured":"Weidemann, S. et al. Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines 9, 397 (2021).","journal-title":"Biomedicines"},{"key":"63269_CR41","doi-asserted-by":"publisher","first-page":"26744","DOI":"10.18632\/oncotarget.15814","volume":"8","author":"S Inaguma","year":"2017","unstructured":"Inaguma, S. et al. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget 8, 26744\u201326754 (2017).","journal-title":"Oncotarget"},{"key":"63269_CR42","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-22-0073","volume":"21","author":"S Tomar","year":"2022","unstructured":"Tomar, S. et al. Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor T cells with increased tumor infiltration and persistence for treating solid tumors. Mol. Cancer Ther. 21, 1195\u20131206 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"63269_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s002800050995","volume":"44","author":"JC Mirsalis","year":"1999","unstructured":"Mirsalis, J. C. et al. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother. Pharm. 44, 395\u2013402 (1999).","journal-title":"Cancer Chemother. Pharm."},{"key":"63269_CR44","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1535-7163.MCT-24-0087","volume":"23","author":"HD Neff-LaFord","year":"2024","unstructured":"Neff-LaFord, H. D. et al. The vedotin antibody-drug conjugate payload drives platform-based nonclinical safety and pharmacokinetic profiles. Mol. Cancer Ther. 23, 1483\u20131493 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"63269_CR45","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41557-024-01507-y","volume":"16","author":"T Journeaux","year":"2024","unstructured":"Journeaux, T. & Bernardes, G. J. L. Homogeneous multi-payload antibody-drug conjugates. Nat. Chem. 16, 854\u2013870 (2024).","journal-title":"Nat. Chem."},{"key":"63269_CR46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","volume":"35","author":"S Peters","year":"2024","unstructured":"Peters, S. et al. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions\u2014a position statement from the ETOP IBCSG Partners Foundation. Ann. Oncol. 35, 607\u2013629 (2024).","journal-title":"Ann. Oncol."},{"key":"63269_CR47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40264-021-01069-9","volume":"44","author":"FA Lievano","year":"2021","unstructured":"Lievano, F. A., Scarazzini, L. J., Tyczynski, J. E., Schubert, C. M. & Renz, C. L. Risk Minimization of antibody-drug conjugates in oncology: a review. Drug Saf. 44, 733\u2013742 (2021).","journal-title":"Drug Saf."},{"key":"63269_CR48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/bc200591x","volume":"23","author":"M Simon","year":"2012","unstructured":"Simon, M., Zangemeister-Wittke, U. & Pluckthun, A. Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjug. Chem. 23, 279\u2013286 (2012).","journal-title":"Bioconjug. Chem."},{"key":"63269_CR49","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1158\/0008-5472.CAN-09-2724","volume":"70","author":"C Zahnd","year":"2010","unstructured":"Zahnd, C. et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 70, 1595\u20131605 (2010).","journal-title":"Cancer Res."},{"key":"63269_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/protein\/gzx022","volume":"30","author":"D Steiner","year":"2017","unstructured":"Steiner, D. et al. Half-life extension using serum albumin-binding DARPin\u00ae domains. Protein Eng. Des. Sel. 30, 583\u2013591 (2017).","journal-title":"Protein Eng. Des. Sel."},{"key":"63269_CR51","doi-asserted-by":"publisher","first-page":"15779","DOI":"10.1021\/acsnano.2c04162","volume":"16","author":"C Ngambenjawong","year":"2022","unstructured":"Ngambenjawong, C., Chan, L. W., Fleming, H. E. & Bhatia, S. N. Conditional antimicrobial peptide therapeutics. ACS Nano 16, 15779\u201315791 (2022).","journal-title":"ACS Nano"},{"key":"63269_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control Release 132, 171\u2013183 (2008).","journal-title":"J. Control Release"},{"key":"63269_CR53","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/pharmaceutics14040728","volume":"14","author":"H Cho","year":"2022","unstructured":"Cho, H., Jeon, S. I., Ahn, C. H., Shim, M. K. & Kim, K. Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation. Pharmaceutics 14, 728 (2022).","journal-title":"Pharmaceutics"},{"key":"63269_CR54","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/ijms25084246","volume":"25","author":"SM Deyev","year":"2024","unstructured":"Deyev, S. M. et al. Preclinical evaluation of HER2-targeting DARPin G3: impact of albumin-binding domain (ABD) fusion. Int. J. Mol. Sci. 25, 4246 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"63269_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120381","volume":"266","author":"J Garousi","year":"2021","unstructured":"Garousi, J. et al. Radionuclide therapy using ABD-fused ADAPT scaffold protein: proof of principle. Biomaterials 266, 120381 (2021).","journal-title":"Biomaterials"},{"key":"63269_CR56","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","volume":"286","author":"JT Andersen","year":"2011","unstructured":"Andersen, J. T. et al. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem. 286, 5234\u20135241 (2011).","journal-title":"J. Biol. Chem."},{"key":"63269_CR57","doi-asserted-by":"publisher","first-page":"108213","DOI":"10.1016\/j.biotechadv.2023.108213","volume":"67","author":"N Porebska","year":"2023","unstructured":"Porebska, N. et al. Multivalent protein-drug conjugates\u2014an emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells. Biotechnol. Adv. 67, 108213 (2023).","journal-title":"Biotechnol. Adv."},{"key":"63269_CR58","doi-asserted-by":"publisher","first-page":"121139","DOI":"10.1016\/j.biomaterials.2021.121139","volume":"278","author":"MD Wang","year":"2021","unstructured":"Wang, M. D. et al. Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency. Biomaterials 278, 121139 (2021).","journal-title":"Biomaterials"},{"key":"63269_CR59","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.19.02085","volume":"38","author":"R Hassan","year":"2020","unstructured":"Hassan, R. et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J. Clin. Oncol. 38, 1824\u20131835 (2020).","journal-title":"J. Clin. Oncol."},{"key":"63269_CR60","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","volume":"23","author":"HL Kindler","year":"2022","unstructured":"Kindler, H. L. et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 23, 540\u2013552 (2022).","journal-title":"Lancet Oncol."},{"key":"63269_CR61","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","volume":"33","author":"AD Santin","year":"2023","unstructured":"Santin, A. D. et al. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int. J. Gynecol. Cancer 33, 562\u2013570 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"63269_CR62","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","volume":"22","author":"LE Lamberts","year":"2016","unstructured":"Lamberts, L. E. et al. ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment. Clin. Cancer Res. 22, 1642\u20131652 (2016).","journal-title":"Clin. Cancer Res."},{"key":"63269_CR63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","volume":"15","author":"CD Weekes","year":"2016","unstructured":"Weekes, C. D. et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol. Cancer Ther. 15, 439\u2013447 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"63269_CR64","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","volume":"28","author":"S Rottey","year":"2022","unstructured":"Rottey, S. et al. Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin. Cancer Res. 28, 95\u2013105 (2022).","journal-title":"Clin. Cancer Res."},{"key":"63269_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/01480545.2021.2005085","volume":"46","author":"J Jiang","year":"2023","unstructured":"Jiang, J. et al. Preclinical safety profile of RC88-ADC: a novel mesothelin-targeted antibody conjugated with monomethyl auristatin E. Drug Chem. Toxicol. 46, 24\u201334 (2023).","journal-title":"Drug Chem. Toxicol."},{"key":"63269_CR66","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1200\/JCO.2024.42.16_suppl.5551","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: results from a first-in-human phase 1\/2 study. J. Clin. Oncol. 42, 5551 (2024).","journal-title":"J. Clin. Oncol."},{"key":"63269_CR67","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","volume":"13","author":"S Golfier","year":"2014","unstructured":"Golfier, S. et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol. Cancer Ther. 13, 1537\u20131548 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"63269_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/srep09928","volume":"5","author":"YF Zhang","year":"2015","unstructured":"Zhang, Y. F. et al. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma. Sci. Rep. 5, 9928 (2015).","journal-title":"Sci. Rep."},{"key":"63269_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1711-1","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 10, 476 (2019).","journal-title":"Cell Death Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63269-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:04:32Z","timestamp":1757426672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63269"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63269-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7889"}}